In the present study, cytocidal potency of CIS was also attenuated by pre-exposing HepG2 cells to menthol, suggesting that the development of MDR attributed to menthol exposure is common across anticancer drugs serving as substrates of MRP2, leading to serious issues associated with therapeutic failure. This evidence concerns the gene ABCC2 and in situ carcinoma.